2020年8月30日 · In the network meta-analysis, acalabrutinib plus obinutuzumab (Aca + Obi) improved PFS than ibrutinib plus obinutuzumab (Ibu + Obi) (HR:0.43, p = .02) and venetoclax plus obinutuzumab (Ven + Obi) (HR:0.30, p < .001) as IRC assessment.

2024年9月1日 · These new drugs, also called targeted therapies, include, for example, new monoclonal antibodies (ofatumumab (OFA), obinutuzumab (OBI)), BTK inhibitors (first generation: ibrutinib (IBR), second generation: acalabrutinib (ACA), zanubrutinib (ZAN)), 3-kinase phosphatidylinositol inhibitor (idelalisib), and BCL-2 inhibitor (venetoclax, VEN).

2023年3月23日 · The ORR with ACA (89.9%) also was significantly higher versus Obi-Chl. In patients from arm A, the most frequent AEs in grades 1–2 were neutropenia (45%) and infusion‐related reactions (39.6%).

In the network meta-analysis, acalabrutinib plus obinutuzumab (Aca + Obi) improved PFS than ibrutinib plus obinutuzumab (Ib …

The ORR with ACA (89.9%) also was significantly higher versus Obi-Chl. In patients from arm A, the most frequent AEs in grades 1–2 were neutro-penia (45%) and infusion-related reactions (39.6%).

it in favour of ACA-OBI and ACA compared to CHL-OBI. A post-hoc, exploratory analysis was conducted to compare IRC-assessed PFS between the two acalabrutinib treatment groups, which showed a reduction in the risk of disease progression or death (i.e., 51%) with ACA-O

首页文章详情页 点赞 收藏 医学界综合整理 分享： 提交评论Aca±Obi方案治疗初治CLL，疗效超Obi+Clb

The ELEVATE-TN trial is a randomized, open-label, phase III superiority trial of ACA-OBI and ACA, respectively, compared to CHL- OBI in adult patients (≥ 65 years or between 18 to 64 years old with comorbidities) with previously untreated CLL.2ELEVATE-TN demonstrated a clinically and statistically significant difference in IRC-assessed PFS ...

he reported results should be interpreted with caution. The comparison of acalabrutinib monotherapy with CLB-OBI (and ACA-OBI) uses the best available data from the ELEVATE-TN trial. The results of this analysis suggests that acalabrutinib monotherapy is more effective and more costly than CLB-OBI (ICER = $65,672 per QALY), and associated with ...

2019年8月29日 · Acalabrutinib/Obinutuzumab Jennifer A. Woyach, The Ohio State University Comprehensive Cancer Center, Columbus, OH/USA, präsentierte die 3-Jahres-Follow-up-Daten einer Phase-I/II-Studie, in der die Therapie mit Aca/Obi bei therapienaiven (tn) Patienten und solchen mit r/r CLL geprüft wird.